Synthesis of CoFe2O4/BiOI nanocomposite; Its application as an antibacterial agent

The antibacterial properties of CFO/BiOI nanocomposite were investigated in our current study because of their importance in Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, and Bacillus cereus. MIC, MBC, Disk Diffusion, and IC50 tests cefalotin (CF), amoxicillin (AMX), gentamicin (GM), Trimethoprim-sulphamethoxazole (SXT), and Ceftriaxone (CRO) antibiotics in concentration 30, 10, 10, 25, and 30 mu g were used, respectively. Various techniques such as X-ray diffraction (XRD), scanning electron microscope (SEM), high-resolution mapping, and energy dispersive X-ray spectroscopy (EDAX) have been used to determine the properties of produced nanocomposites. The results showed CFO/BiOI nanocomposite exhibits strong significant biological activity against B. cereus. The results of MBC (minimum bactericidal concentration) and MIC (Minimum Inhibition Concentration) tests for CFO/BiOI nanocomposites on bacteria were examined in the range of 0.12-0.48 and 0.06 to 0.24 mg ml(-1), respectively. According to the results,, the minimum IC50 value was determined at a concentration of 0.061 mg ml(-1). On the other hand, the most resisting and susceptible bacteria in this method were P. aeruginosa and B. cereus, respectively. These findings are identical to a prior study on antibacterial properties of CoFe2O4 nanoparticles. The MBC endpoint is defined as the lowest concentration, which killed 98% of the bacterial population.